Company Initiates Institutional ETH Accumulation Strategy
PALO ALTO, Calif., Aug. 12, 2025 /PRNewswire/ — 180 Life Sciences Corp. (Nasdaq: ATNF), *dba* ETHZilla (the “Company”, “180 Life Sciences” or “ETHZilla”), announced today it has amassed a considerable Ethereum (ETH) treasury, holding 82,186 ETH acquired at an average price of $3,806.71. This ETH stake is currently valued at approximately $349 million. In addition to its Ether holdings, ETHZilla maintains a substantial cash reserve of roughly $238 million in USD cash equivalents.
“Since completing our PIPE transaction last week, ETHZilla has deployed over $350 million in capital, strategically building a differentiated Ethereum treasury vehicle,” stated McAndrew Rudisill, Executive Chairman of the Company. ” Crucially, we anticipate this ETH reserve will unlock significant cash flow for our shareholders as we execute our on-chain yield generation program in collaboration with our external asset manager, Electric Capital. We believe their expertise will unlock considerable value for ETHZilla.”
As of August 11, 2025 (except for shares outstanding, which is as of August 5, 2025), ETHZilla’s current ETH position and key metrics are summarized below:
- Total ETH & ETH Equivalents Held: 82,186
- Total ETH & ETH Equivalents Held (USD): approximately $349 million
- Total USD Cash Equivalents: approximately $238 million
- Total Shares Outstanding: 154.032 million
The most recently acquired ETH is earmarked for long-term holding and staking via Electric Capital’s proprietary Ethereum network strategies, aiming to generate sustainable yield.
The Company plans to regularly update on its treasury and on-chain yield generation strategies through public releases and regulatory filings, as information becomes available.
About 180 Life Sciences (d/b/a ETHZilla)
With plans to rebrand as ETHZilla Corporation, the company is positioning itself as an institutional player in Ether (ETH) accumulation. ETHZilla aspires to be a leading benchmark for on-chain treasury management among publicly traded companies, developing its strategy with active engagement from the Ethereum community.
ETHZilla’s treasury strategy, powered by its partnership with Electric Capital, seeks to deliver superior yield generation compared to traditional ETH staking methods. The company’s leadership includes capital markets veterans, prominent Ethereum engineers, leading DeFi founders, infrastructure pioneers, and other influential figures in the ecosystem. This council will help ensure the treasury assets are managed to the best of its abilities, and take advantage of on-chain opportunities as they become available.
Originally founded as an innovative biotechnology company, 180 Life Sciences is strategically pivoting towards software-enabled gaming and entertainment. Alongside its newly announced ETH treasury strategy and existing plans to monetize its biotech assets, the company remains committed to accelerating the deployment and development of its gaming initiatives, setting the stage for a new focus on the digital world.
Forward Looking Statements
This press release contains “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, including, but not limited to, the successful and timely completion of the previously disclosed PIPE offering, convertible note offering, and related transactions; the realization of anticipated benefits from these transactions, including the company’s digital asset treasury strategy; the company’s ability to achieve profitable operations; fluctuations in the market price of ETH; government regulation of cryptocurrencies and online betting; changes in securities laws and regulations; and other business, market, financial, political, and regulatory risks. Additional risks include the company’s ability to repay its outstanding convertible notes, the highly volatile nature of Ether and cryptocurrency prices, increased competition in the industries in which the company operates, legal, commercial, regulatory, and technical uncertainty regarding digital assets, the treatment of crypto assets for U.S. and foreign tax purposes, potential litigation, global economic conditions, geopolitical events, access to additional financing, and the company’s ability to raise funding. The accuracy of these statements are subject to risks and events that could cause material differences in expected versus actual results. For a comprehensive discussion of these and other risks and uncertainties, investors are encouraged to review the company’s filings with the SEC, available at www.sec.gov. Given these uncertainties, undue reliance should not be placed on these statements. Moreover, the forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update any forward-looking statements except as required by law. Investors should also be aware that under U.S. GAAP, certain crypto assets must be measured at fair value, with changes recognized in net income for each reporting period. These fair value adjustments may cause significant fluctuations in the Company’s balance sheet and income statement from period-to-period. In addition, for certain crypto assets, including ETH, which the Company holds, impairment charges may be required to be reported in net income if the market price of such assets (including ETH) falls below the cost basis at which those assets are carried on the balance sheet.
View original content to download multimedia:https://www.prnewswire.com/news-releases/180-life-sciences-ethzilla-holds-82-186-eth-302527693.html
SOURCE 180 Life Sciences Corp.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/7018.html
